Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SANGUINE CORP. (SGNC) -- Ignore unavailable to you. Want to Upgrade?

To: drdan who wrote (210)	6/11/1998 8:19:00 PM
From: Gwolf	Read Replies (2) \| Respond to of 5402

Dr. Dan, Those are questions for Dr. Drees, he has been at this for years and can answer your questions. All of these issues should have been addressed during the FDA approval process back in the 80's. They received approval so there is obviously answers to those questions. My suggestion is to call Dr.Drees and get the answers first hand, I think your response would be very helpful considering you are a medical professional and would understand his responses where most of us wouldn't. Gwolf

To: drdan who wrote (210)	6/12/1998 12:29:00 AM
From: chirodoc	Respond to of 5402

Dr. D you have some great questions. this is what i have gotten from researching pfcs. as you know they bind to oxygen like a bee to honey. there seems to be very little anaphylaxis in animal studies and very little clottingproblems. the major problem has been the emulsion that it is placed in. that is where dr. drees has his emphasis and i, like gwolf, would love to have you talk to him. did you read the scientific american article that i posted. great review. please give us your feedback! curtis